Since the mechanism of action of the 2′‐O‐methoxyethyl phosphorothioate‐modified drug nusinersen, a currently approved ASO therapy for SMA patients, consists of promoting exon 7 inclusion into SMN2 pre‐mRNA by blocking the recruitment of HNRNP splicing repressors at the ISS‐N1 site (Chiriboga et al, 2016; Finkel et al, 2016, 2017; Haché et al, 2016; Mercuri et al, 2018), we postulated that a combinatorial treatment with MS023 would synergistically lead to improved therapeutic benefit and allow for a cost‐effective ASO dosing regimen in SMA. Here, SMN2 is linked to proximal spinal muscular atrophy.